Phoenix, AZ  |  March 24-27

We’ve reached a pivotal moment in the history of pharmacy; we are on the cusp of great changes that will affect the profession on all levels. At APhA2023, we’re rising to bring together pharmacists from all practice settings and experience levels to learn, connect, and create opportunities to transform the future of pharmacy, together.

Skyline of Phoenix, AZ

Keynote Speakers

Keynote Speaker Inky Johnson APhA2023 keynotes will share their experiences of addressing adversity, embracing opportunities, and rising to meet challenges.

View keynote speakers  

19 Education Tracks

Personalize your experience with the more than 100 educations sessions across 19 educational tracks.

View education  

Schedule At a Glance

Check out the highlights of each day and customize your schedule.

View events  


The APhA Awards and Honors Program is the profession’s most comprehensive recognition program. Come celebrate your colleagues!

Awards info  

Visit Phoenix

Nestled in the mountains of the Sonoran Desert, you’ll find art, food, adventure, history, and a place to relax among iconic landscapes. Plan your trip today!

Learn more  

APhA2023 logo

Practice Advancement Opportunities

Training to support your practice


Latest from APhA

View CEO Blog

Reflecting on American Pharmacists Month

With American Pharmacists Month (APhM) behind us, I wanted to take a moment to celebrate the spotlights that shined on our profession, focusing on our pharmacists, student pharmacists, pharmacy technicians, and the incredible work that they do. We saw APhM recognized across social media channels, state proclamations by governors, and even through an on-camera shout out at the TODAY Show on their plaza. This well-deserved recognition goes a long way in sharing with the world the value and importance of pharmacists and pharmacy personnel in all settings.


APhA applauds new federal bipartisan PBM legislation

The American Pharmacists Association (APhA) applauds the introduction of the Drug Price Transparency in Medicaid Act, which would reign in PBMs’ unfair and anticompetitive business practices that are harming the viability of our nation’s pharmacies.


Pharmacy news

View all news

FDA panel OKs Paxlovid as COVID-19 treatment

An FDA advisory panel backed the use of Pfizer’s nirmatrelvir/ritonavir antiviral (Paxlovid) as a treatment for adults with COVID-19 who are at high risk for severe illness. The endorsement is expected to allow the drug, which is available under an EUA, to receive full FDA approval.

Statin alternative joins drugs that could reduce heart attack risk

A new study published in NEJM found that bempedoic acid (Nexletol—Esperion Therapeutics) modestly reduced the risk of heart attacks, strokes, and other complications from heart disease. However, it did not reduce the overall mortality rate. Bempedoic acid was approved by FDA 3 years ago to reduce low-density lipoprotein (LDL) levels.